Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE. Rome II. The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment; a Multinational Consensus. McLean, VA : Degnon Associates, 2000.
3
0033992829
Epidemiologic study of the irritable bowel syndrome in Beijing: Stratified randomized study by cluster sampling
Pan G, Lu S, Ke M, Han S, Guo H, Fang X. Epidemiologic study of the irritable bowel syndrome in Beijing: stratified randomized study by cluster sampling. Chin. Med. J. (Engl.) 2000 113 : 35 9.
A population-based epidemiologic study of irritable bowel syndrome in South China: Stratified randomized study by cluster sampling
Xiong LS, Chen MH, Chen HX, Xu AG, Wang WA, Hu PJ. A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling. Aliment. Pharmacol. Ther. 2004 19 : 1217 24.
The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an Asian urban community
Gwee KA, Wee S, Wong ML, Png DJ. The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an Asian urban community. Am. J. Gastroenterol. 2004 99 : 924 31.
Current patterns of irritable bowel syndrome in Taiwan: The Rome II questionnaire on a Chinese population
Lu CL, Chen CY, Lang HC et al. Current patterns of irritable bowel syndrome in Taiwan: the Rome II questionnaire on a Chinese population. Aliment. Pharmacol. Ther. 2003 18 : 1159 69.
Effects of tegaserod on Fos, substance P and calcitonin gene-related peptide expression induced by colon inflammation in lumbarsacral spinal cord
Sun YN, Luo JY. Effects of tegaserod on Fos, substance P and calcitonin gene-related peptide expression induced by colon inflammation in lumbarsacral spinal cord. World J. Gastroenterol. 2004 10 : 1830 83.
Tegaserod inhibits noxious rectal distention induced responses and limbic system c-Fos expression in rats with visceral hypersensitivity
Jiao HM, Xie PY. Tegaserod inhibits noxious rectal distention induced responses and limbic system c-Fos expression in rats with visceral hypersensitivity. World J. Gastroenterol. 2004 10 : 2836 41.
The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo
Beattie DT, Smith JA, Marquess D et al. The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br. J. Pharmacol. 2004 143 : 549 60.
Tegaserod is safe, well tolerated and effective in the treatment of patients with non-diarrhoea irritable bowel syndrome
Fried M, Beglinger C, Bobalj NG, Minor N, Coello N, Michetti P. Tegaserod is safe, well tolerated and effective in the treatment of patients with non-diarrhoea irritable bowel syndrome. Eur. J. Gastroenterol. Hepatol. 2005 17 : 421 7.
Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation
Müller-Lissner SA, Fumagalli I, Bardhan KD et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment. Pharmacol. Ther. 2001 15 : 1655 66.
A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation
Novick J, Miner P, Krause R et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. 2002 16 : 1877 88.
A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation (IBS-C)
Tack J, Müller-Lissner S, Bytzer P et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation (IBS-C). Gut 2005 54 : 1707 13.
Tegaserod provides relief of symptoms in female patients with irritable bowel syndrome (IBS) suffering from abdominal pain and discomfort, bloating and constipation
A. 22.
Lefkowitz M, Ligozio G, Lebas K, Heggland JE, Rueegg PC. Tegaserod provides relief of symptoms in female patients with irritable bowel syndrome (IBS) suffering from abdominal pain and discomfort, bloating and constipation. Gastroenterology 2001 120 : 104 : A 22.
An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome
Kellow J, Lee OY, Chang FY et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003 52 : 671 6.
Drossman DA, Richter JE, Talley NJ, Thompson WG, Corazziari E, Whitehead WE. Rome. The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment: a Multinational Consensus. McLean, VA : Degnon Associates, 1994.
24
3042525813
A randomized, double-blind, placebo-controlled, multicenters study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome
(In Chinese.)
Lin SR, Tegaserod Clinical Research G. [A randomized, double-blind, placebo-controlled, multicenters study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome]. Zhonghua Nei Ke Za Zhi 2003 42 : 88 90. (In Chinese.)
Efficacy and tolerability of tegaserod in constipation dominant Irritable Bowel Syndrome
Shah SH, Jafri SW, Gul M et al. Efficacy and tolerability of tegaserod in constipation dominant Irritable Bowel Syndrome. J. Coll. Physicians Surg. Pak. 2004 14 : 21 4.
Diarrhea in patients treated with tegaserod for irritable bowel syndrome with constipation (IBS-C) is infrequent and usually self-limited
Earnest D, Ruegg P, Dunger-Baldauf C, Lefkowitz M. Diarrhea in patients treated with tegaserod for irritable bowel syndrome with constipation (IBS-C) is infrequent and usually self-limited. Am. J. Gastroenterol. 2002 97 (9 Suppl. S277.
Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation
Müller-Lissner S, Holtmann G, Rueegg P, Weidinger G, Loffler H. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. 2005 21 : 11 20.